Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Go back to Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study| Gilead Sciences (NASDAQ: GILD) | Delayed: 123.76 -1.69 (1.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $125.45 | 52 Week High | $108.63 | |||
| Open | $125.85 | 52 Week Low | $71.39 | |||
| Day High | $126.39 | P/E | 68.38 | |||
| Day Low | $122.43 | EPS | $1.81 | |||
| Volume | 14,348,344 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 113.87 -1.57 (1.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $115.44 | 52 Week High | $65.46 | |||
| Open | $114.64 | 52 Week Low | $47.97 | |||
| Day High | $114.94 | P/E | 77.46 | |||
| Day Low | $111.57 | EPS | $1.47 | |||
| Volume | 29,522,568 | |||||
